Mutations of p53 tumor suppressor gene increase with tumor progression in colorectal cancers. In this study, we examined the expressions of p33ING1, p14ARF, MDM2 and p21WAF1 mRNA in 25 advanced colorectal cancers by quantitative RT-PCR method, and compared the expression levels of p33ING1, p14ARF, p21WAF1 and MDM2 in relation to p53 status in the tumors. Fifteen of 25 colorectal cancers (60%) showed abnormal accumulation of p53 protein in the nucleus, and the remaining 10 colorectal cancers (40%) were negative for p53 immunostaining. We found a G --> T transition (nonsense mutation) at the first nucleotide of codon 298 (exon 8) in one p53-negative case, and a frame shift mutation on exon 7 in another p53-negative case. In remaining eight p53-negative cases, there was no mutation in the entire open reading frame of p53 cDNA. Interestingly, in eight cases with p53 wild-type gene, 6 cases (75%) showed a marked down-regulation of p14ARF mRNA, and three cases (37.5%) over-expressed MDM2 mRNA. Only one case with wild-type p53 gene showed normal level expression of p53 regulatory-factors (p33ING1, p14ARF, and MDM2). Thus, p53 tumor suppressor pathway was disrupted in 24 of 25 colorectal cancers (96%).
Download full-text PDF |
Source |
---|
Endocr Relat Cancer
January 2025
T Vandamme, NETwerk and department of Digestive Oncology, University Hospital Antwerp, Edegem, Belgium.
Gastroenteropancreatic neuroendocrine neoplasms(GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO introduced the neuroendocrine tumour(NET) grade 3 (G3) subgroup, characterized by Ki-67>20% and a well-differentiated morphology and poorly differentiated neuroendocrine carcinomas(NEC) (Ki-67>20%). Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain.
View Article and Find Full Text PDFColorectal Dis
February 2025
Department of Gastrointestinal Surgery, Institute of Science Tokyo, Tokyo, Japan.
Aim: Understanding of kidney function decline (KFD) after pelvic exenteration (PE) for colorectal cancer remains limited, and the effects of a long ileal conduit (IC) on kidney disorders are unclear. The aim of this study was to investigate long-term kidney function following PE in colorectal cancer and to evaluate the effects of IC length on KFD.
Method: This was a retrospective, single-centre cohort study.
Colorectal Dis
February 2025
Colorectal Surgery Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Colorectal Dis
February 2025
Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Aim: Accumulated data suggest that routine use of defunctioning stoma in low anterior resection for rectal cancer may cause kidney injury, bowel dysfunction and a higher risk of permanent stomas. We aim to study whether avoidance of a diverting stoma in selected patients is safe and reduces adverse consequences.
Methods: SELSA is a multicentre international prospective observational study nesting an open-label randomized clinical trial.
Histopathology
January 2025
Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
Aims: We compiled two cohorts of colorectal adenosquamous carcinoma (ASC) to describe its histologic and molecular aspects using modern parameters to compare them with literature reports using meta-analysis of cohorts and individual case series.
Methods And Results: We identified 53 colorectal ASC from 19 North American academic medical centres, in addition to national database reports on 94 Dutch cases. We analysed available clinical, histologic, and immunohistochemical features and patient outcome.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!